News | July 29, 2025
Astec LifeSciences Q1 FY26 revenue up 30.3%
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Global specialty pipeline accelerates growth
Subscribe To Our Newsletter & Stay Updated
